CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

Endpoints News
Original article

GSK strikes deal for Chimagen’s T cell engager for blood cancer

PartnershipPositive
AI Analysis

Summary

GSK has entered into a licensing agreement with Chimagen Biosciences for a trispecific T cell engager targeting blood cancer, marking the second deal between the two companies in two years.

Importance:6/10
Sentiment:
0.50
licensingpartnershipT cell engageroncologyGSKChimagen
Related Companies

Read the original article

Published by Endpoints News on September 15, 2026 11:03 AM

Read Original